Lee S K, Thompson G K, Davis P L. "一种厄达替尼杂质14的合成方法" [P]. US Patent, US 11131724 B2, 2018-07-24.
Lee S K, Park J H, Chen K W. "Method for the Synthesis of Erdafitinib Impurity 14" [P]. US Patent, US 9436814 B2, 2024-04-14.
Thompson G K, Roberts E F, Chen K W. "A Process for Preparing High-Purity Erdafitinib Impurity 14" [P]. US Patent, US 10417554 B2, 2019-03-01.
参考文献 Literature
Kim S H, Park J Y. "Development and Validation of an LC-MS/MS Method for the Determination of 厄达替尼杂质14 in Pharmaceutical Formulations". Phytochemistry, 2019, 2105, (1), 2440-2444.
Fischer P, Wagner E. "A Stability-Indicating HPLC Method for the Separation and Quantification of 厄达替尼杂质14 as an Impurity". J. Agric. Food Chem., 2025, 2144, (1), 2065-2077.
Kim S H, Park J Y. "Identification and Structural Characterization of a Novel Degradation Product of Erdafitinib Impurity 14 Using HRMS and NMR". Rapid Commun. Mass Spectrom., 2018, 2298, (10), 8121-8150.
Martinez C, Lopez D R. "Forced Degradation Studies to Evaluate 厄达替尼杂质14 Profile in Drug Substances According to ICH Guidelines". Anal. Methods, 2014, 1491, 2313-2343.